Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti‐cardiac fibrosis activity
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Yu-Xuan Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China. Hauptthemen laut MEDLINE: Imidazoles, Molecular Docking Simulation, Receptor, Transforming Growth Factor-beta Type I, Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province, National Natural Science Foundation of China, Higher Education Discipline Innovation Project.
Abstract (Originalsprache)
Three series of N ‐{[4‐([1,2,4]triazolo[1,5‐ α ]pyridin‐6‐yl)‐5‐(6‐methylpyridin‐2‐yl)‐1 H ‐imidazol‐2‐yl]methyl}acetamides ( 14a – d , 15a – n , and 16a – f ) were synthesized and evaluated for activin receptor‐like kinase 5 (ALK5) inhibitory activities in an enzymatic assay. The target compounds showed high ALK5 inhibitory activity and selectivity. The half maximal inhibitory concentration (IC 50 ) for phosphorylation of ALK5 of 16f (9.1 nM), the most potent compound, was 2.7 times that of the clinical candidate EW‐7197 (vactosertib) and 14 times that of the clinical candidate LY‐2157299. The selectivity index of 16f against p38α mitogen‐activated protein kinase was >109, which was much higher than that of positive controls (EW‐7197: >41, and LY‐2157299: 4). Furthermore, a molecular docking study provided the interaction modes between the target compounds and ALK5. Compounds 14c , 14d , and 16f effectively inhibited the protein expression of α‐smooth muscle actin (α‐SMA), collagen I, and tissue inhibitor of metalloproteinase 1 (TIMP‐1)/matrix metalloproteinase 13 (MMP‐13) in transforming growth factor‐β‐induced human umbilical vein endothelial cells. Compounds 14c and 16f showed especially high activity at low concentrations, which suggests that these compounds could inhibit myocardial cell fibrosis. Compounds 14c , 14d , and 16f are potential preclinical candidates for the treatment of cardiac fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China.
- Interdisciplinary Program of Biological Function Molecules, College of Integration Science, Yanbian University, Yanji, China.
Förderung
- Natural Science Foundation of Jilin Province
- National Natural Science Foundation of China
- Higher Education Discipline Innovation Project
Zitieren
APA
Yang, Y. X., Guo, J., Liu, C., Nan, J. X., Wu, Y. L., & Jin, C. H. (2024). Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti‐cardiac fibrosis activity. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400131
Vancouver
Yang YX, Guo J, Liu C, Nan JX, Wu YL, Jin CH. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti‐cardiac fibrosis activity. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400131
BibTeX
@article{Yang2024,
author = {Yang, Yu-Xuan and Guo, Jia and Liu, Chuang and Nan, Ji-Xing and Wu, Yan-Ling and Jin, Cheng-Hua},
title = {Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti‐cardiac fibrosis activity},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400131}
}
EUVIMED